Back to Interventions
Substance / Medication

Glutamic acid

SNOMED 85214009UMLS C0061472

Overview

Active Ingredient
glutamate
RxNorm CUI
70602

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Short bowel syndrome
Acquired short bowel syndrome

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

1 trials linked to this intervention

1
Total Trials
0
Recruiting
0
With Results

Recent Trials

Evaluation of Aminobutyric Acid, Glutamic Acid, Calcium, Thiamine, Pyridoxine and Cyanocobalamin as Therapy for Vertigo

NCT05221892Phase 4Completed334 enrolled
View all 1 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:
Rituximab in stiff-person syndrome with glutamic acid decarboxylase 65 autoantibody: a systematic review.
Pignolo Antonia, Vinciguerra Claudia, Monastero Roberto et al. · J Neurol · 2025
PMID: 40413341Meta-AnalysisFull text (PMC)
Association between treatment effect on C-peptide preservation and HbA1c in meta-analysis of glutamic acid decarboxylase (GAD)-alum immunotherapy in recent-onset type 1 diabetes.
Nowak Christoph, Hannelius Ulf, Ludvigsson Johnny · Diabetes Obes Metab · 2022
PMID: 35434906Meta-AnalysisFull text (PMC)
Psychiatric symptoms in anti glutamic acid decarboxylase associated limbic encephalitis in adults: a systematic review.
Vrillon Agathe, Carle Guilhem, Berzero Giulia et al. · Neurosci Biobehav Rev · 2020
PMID: 33022299Meta-Analysis
Autoantibodies against voltage-gated potassium channel and glutamic acid decarboxylase in psychosis: A systematic review, meta-analysis, and case series.
Grain Rosemary, Lally John, Stubbs Brendon et al. · Psychiatry Clin Neurosci · 2017
PMID: 28573688Meta-Analysis
Association between a genetic variant related to glutamic acid metabolism and coronary heart disease in individuals with type 2 diabetes.
Qi Lu, Qi Qibin, Prudente Sabrina et al. · JAMA · 2013
PMID: 23982368Meta-AnalysisFull text (PMC)
Intralymphatic glutamic acid decarboxylase administration in type 1 diabetes patients induced a distinctive early immune response in patients with DR3DQ2 haplotype.
Puente-Marin Sara, Dietrich Fabrícia, Achenbach Peter et al. · Front Immunol · 2023
PMID: 36817467RCTFull text (PMC)
Glutamic acid intake by formula-fed infants: are acceptable daily intakes appropriate?
Mennella Julie A, Smethers Alissa D, Delahanty Michelle T et al. · Eur J Pediatr · 2023
PMID: 37776354RCTFull text (PMC)
Efficacy of N-acetyl aspartyl glutamic acid versus fluorometholone for treating allergic conjunctivitis in an environmental exposure chamber.
de Blay Frédéric, Gherasim Alina, Domis Nathalie et al. · Clin Exp Allergy · 2022
PMID: 35302688RCTFull text (PMC)
A randomized trial of oral gamma aminobutyric acid (GABA) or the combination of GABA with glutamic acid decarboxylase (GAD) on pancreatic islet endocrine function in children with newly diagnosed type 1 diabetes.
Martin Alexandra, Mick Gail J, Choat Heather M et al. · Nat Commun · 2022
PMID: 36566274RCTFull text (PMC)
Gamma-Polyglutamic Acid-Rich Natto Suppresses Postprandial Blood Glucose Response in the Early Phase after Meals: A Randomized Crossover Study.
Araki Risa, Yamada Takeshi, Maruo Kazushi et al. · Nutrients · 2020
PMID: 32784412RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Glutamic acid (substance)
SNOMED CT
85214009
UMLS CUI
C0061472
RxNorm CUI
70602

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
1
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.